CAMBRIDGE, Mass. (
said Tuesday that the company expects 2010 adjusted earnings per share to be "above" $4.55 on total revenue growth in the mid-single digits.
As it stands, the Street was looking for Biogen to earn $4.37 a share on a pro forma basis with total revenue of $4.51 billion, which represents 3% year-over-year growth.
For the fourth quarter, Biogen said net income totaled $305.6 million, or $1.06 a share, from $206.7 million, or 70 cents a share, in the fourth quarter last year. On an adjusted, or pro forma basis, earnings were $1.20 a share, topping the consensus estimate of $1.05 a share.
Revenue in the fourth quarter totaled $1.13 billion compared to $1.07 billion in the year-ago quarter.
Last month, Biogen pre-announced that sales of its multiple sclerosis drug Tysabri surpassed $1 billion in the 2009, matching Street consensus estimates. Tuesday, Biogen said 2009 Tysabri sales totaled $1.1 billion.
-- Reported by Adam Feuerstein in Boston.
Follow Adam Feuerstein on
Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;
to send him an email.